as 12-17-2024 4:00pm EST
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Founded: | 2018 | Country: | United States |
Employees: | N/A | City: | DALLAS |
Market Cap: | 170.7M | IPO Year: | 2021 |
Target Price: | $100.33 | AVG Volume (30 days): | 107.5K |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -11.56 | EPS Growth: | N/A |
52 Week Low/High: | $6.72 - $92.00 | Next Earning Date: | 11-13-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 2.65% |
TIL Breaking Stock News: Dive into TIL Ticker-Specific Updates for Smart Investing
Zacks
a month ago
GlobeNewswire
a month ago
GuruFocus.com
2 months ago
GuruFocus.com
3 months ago
GuruFocus.com
3 months ago
Motley Fool
3 months ago
Motley Fool
3 months ago
Zacks
3 months ago
The information presented on this page, "TIL Instil Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.